BDBM236787 US9388149, 18::US9580412, Example 18

SMILES CN(CC(F)(F)F)C(=O)c1cccc(Nc2c(N[C@H](C3CCCS3)c3ccc(C)o3)c(=O)c2=O)c1O

InChI Key InChIKey=KBLOFZHBIDLNIS-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 236787   

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM236787(US9388149, 18 | US9580412, Example 18)
Affinity DataIC50: 36nMT: 2°CAssay Description: PathHunter HEK293-CXCR2 or U2OS hCXCR1 β-arrestin cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM236787(US9388149, 18 | US9580412, Example 18)
Affinity DataIC50: 15nMT: 2°CAssay Description: PathHunter HEK293-CXCR2 or U2OS hCXCR1 β-arrestin cells (DiscoveRx Corporation) were seeded overnight at 10 000 cells/well (384-well format) in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/10/2017
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 1(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM236787(US9388149, 18 | US9580412, Example 18)
Affinity DataIC50: 36nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the β-a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2019
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 2(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM236787(US9388149, 18 | US9580412, Example 18)
Affinity DataIC50: 15nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the β-a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2019
Entry Details
Go to US Patent

TargetC-C chemokine receptor type 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM236787(US9388149, 18 | US9580412, Example 18)
Affinity DataIC50: 97nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the β-a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2019
Entry Details
Go to US Patent

TargetC-C chemokine receptor type 6(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM236787(US9388149, 18 | US9580412, Example 18)
Affinity DataIC50: 60nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the β-a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2019
Entry Details
Go to US Patent

TargetC-X-C chemokine receptor type 3(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM236787(US9388149, 18 | US9580412, Example 18)
Affinity DataIC50: 450nMAssay Description:The in vitro affinity of the compounds of the present invention for the CXCR1 and CXCR2 receptors was determined on a functional test of the β-a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2019
Entry Details
Go to US Patent